💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, slow-growing business, priced for perfection.
Gland Pharma is scored on the pharma / healthcare framework. It keeps a healthy 15.2% of every rupee of sales as net profit. Cash broadly tracks reported profit (CFO/PAT 1.00×). Free cash flow is worth about 2.2% of its market value.
Over the last 3 years revenue compounded at 20%/yr and profit at 10%/yr. Book value has grown 9%/yr. Return on equity is a modest 9.9%. In the latest quarter profit fell 14% versus the prior quarter.
At 51× earnings, the stock sits at the 100th percentile of its own 3.6-year range — the expensive end of where it has historically traded. Today's price already implies ~20%/yr earnings growth sustained for a decade — a demanding bar. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 46.33 | — | — |
| P/B | 5.05 | 4.1 | worse |
| EV/EBITDA | 23.85 | 19.33 | worse |
| ROE | 9.92 | — | — |
| ROCE | 14.02 | 14.41 | worse |
| ROA | 9.02 | 1.64 | better |
| Quick Ratio | 3.6 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
20% CAGR over 3 years — high-growth territory. Growth is accelerating — latest year outpaced the prior year's rate.
Revenue is outpacing profit (20% vs 10%) — costs are rising faster than the top line. The latest year saw a +47% swing — check if it's a one-off or structural.
Operating margin has compressed from 27% to 22% — costs or competition are eating into profitability. Margins have declined for 2 consecutive years — watch for a structural cost problem.
ROE at 10% — modest; the capital isn't working hard. Low variance across years — a predictable business that earns steadily on its equity base.
10% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating. Run-rate stepping up — recent quarters average 12% above earlier ones.
Profit fell 14% QoQ — one-quarter drops can be noise, but a pattern matters. Quarterly net margins are expanding (12% → 17%) — profitability per rupee of revenue is improving.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 45.8% — dispersed ownership; institutional flows drive the stock. Promoters reduced 6.1pp over 4 quarters — watch whether this is planned divestment or pledge invocations. FII stake up 2.8pp over 4 quarters — growing foreign interest. Both FII and MF added last quarter — broad institutional confidence.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.